Conferences
SESAUA 2024: Time Interval Between Radium-223 Therapy and 177Lu-PSMA Treatment for mCRPC and Outcomes in the RALU Study
March 25, 2024
SESAUA 2024: Screening with PSA and MRI: Yearly Trends by PI-RADS and Race Shows Stable Diagnosis of NCCN Very Low Risk Disease
March 23, 2024
SESAUA 2024: Association of PSA Response and Overall Survival in Patients with mHSPC: Results from the Phase 3 ARASENS Trial
March 23, 2024
SESAUA 2024: Determining the Genetic Causes of Bladder Cancer in a Family with Heritable Pattern of Bladder Cancer
March 22, 2024
SESAUA 2024: Intravascular Heparinization During IVC Thrombectomy and Perioperative Complications
March 21, 2024